대한의생명과학회지 (Biomedical Science Letters)

  • 제25권2호
  • /
  • Pages.185-189
  • /
  • 2019
  • /
  • 1738-3226(pISSN)
  • /
  • 2288-7415(eISSN)
대한의생명과학회 (The Korean Society for Biomedical Laboratory Sciences)
권호 표지
DOI QR코드

DOI QR Code

Circulating miR-221 and miR-222 as Potential Biomarkers for Screening of Breast Cancer

  • Kim, Jungho (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Oh, Sehee (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Park, Sunyoung (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Ahn, Sungwoo (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Choi, Yeonim (Department of Biomedical Laboratory Science, Songho College) ;
  • Kim, Geehyuk (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Kim, Seung Il (Department of Surgery, College of Medicine, Yonsei University) ;
  • Lee, Hyeyoung (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
  • 투고 : 2019.06.13
  • 심사 : 2019.06.25
  • 발행 : 2019.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Breast cancer is the second most common cancer in women with approximately 522,000 deaths annually worldwide. microRNAs have recently been studied as potential biomarkers that regulate gene expression and are involved in tumorigenesis. Here we evaluated circulating miR-221 and miR-222 as potential biomarkers for breast cancer by quantitative reverse transcription PCR using blood plasma of 30 healthy controls and 30 breast cancer patients. The TNM stage on circulating miR-221 and miR-222 was also investigated. Circulating miR-221 and miR-222 were significantly up-regulated in breast cancer patients compared to those in healthy controls (P < 0.0022 and P = 0.0058, respectively). Furthermore, the relative expression level of circulating miR-221 in patients with stage III breast cancer was higher than in those with stage I and II. Taken together, we have shown circulating miR-221 and miR-222 could be useful biomarkers for the screening of breast cancer patients.

키워드

참고문헌

  1. Achkar NP, Cambiagno DA, Manavella, PA. miRNA biogenesis: A dynamic pathway. Trends Plant Sci. 2016. 21: 1034-1044. https://doi.org/10.1016/j.tplants.2016.09.003
  2. Duffy MJ. CA 15-3 and related mucins as circulating markers in breast cancer. Annals of Clinical Biochemistry. 1999. 36: 579-586. https://doi.org/10.1177/000456329903600503
  3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015. 136: E359-386. https://doi.org/10.1002/ijc.29210
  4. Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G. miR221/222 in cancer: Their role in tumor progression and response to therapy. Current Molecular Medicine. 2012. 12: 27-33. https://doi.org/10.2174/156652412798376170
  5. Li B, Lu Y, Wang H, Han X, Mao J, Li J,Yu L,Wang B, Fan S, Yu X, Song B. miR-221/222 enhance the tumorigenicity of human breast cancer stem cells via modulation of PTEN/Akt pathway. Biomed Pharmacother. 2016. 79: 93-101. https://doi.org/10.1016/j.biopha.2016.01.045
  6. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America. 2008. 105: 10513-10518. https://doi.org/10.1073/pnas.0804549105
  7. Ng EKO, Li R, Shin VY, Siu JM, Ma ESK, Kwong A. MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells. Tumor Biology. 2014. 35: 2591-2598. https://doi.org/10.1007/s13277-013-1341-7
  8. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002. 30: e36. https://doi.org/10.1093/nar/30.9.e36
  9. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018. 68: 7-30. https://doi.org/10.3322/caac.21442
  10. Song JL, Ouyang YM, Che JY, Li XM, Zhao Y, Yang KJ, Zhao XT, Chen YH, Fan CY, Yuan WE. Potential Value of miR-221/222 as diagnostic, prognostic, and therapeutic biomarkers for diseases. Frontiers in immunology. 2017. 8.
  11. Yu DC, Li QG, Ding XW, Ding YT. Circulating microRNAs: potential biomarkers for cancer. Int J Mol Sci. 2011. 12: 2055-2063. https://doi.org/10.3390/ijms12032055